Outer Biosciences has come out of stealth after four years, keeping surgically discarded human skin alive for up to a month and feeding the results into an AI model that predicts useful compounds. It has raised about $23mn and employs 19 people.
A company in Massachusetts has spent four years keeping human skin alive outside the body. Outer Biosciences says it can hold surgically discarded tissue viable for up to a month, and it has been running experiments on it the whole time without telling anyone.
The point of the tissue is to teach a model. An AI system predicts which untested chemicals should affect a particular skin function, the living tissue tests the prediction, and the result goes back into the model whether it was right or wrong.
The pace changed when that loop closed. Early work using scientific literature produced a couple of leads in about 18 months, while the company now says it generates a candidate roughly every six weeks.
The material comes from surgery, mostly cosmetic. Outer sources it through biobanks and brokers operating under institutional review board oversight and documented donor consent, with identifiers stripped before it arrives, and says it pays fees on a cost recovery basis rather than buying tissue.
The technical claim is about time rather than novelty. Living tissue is usually usable for days, which is enough for acute toxicity and not much else, while collagen remodelling, pigmentation change and barrier repair take weeks to happen.
Outer says a month-old sample still resembles a day-one sample without being identical to it. That is a carefully hedged claim and the company makes it carefully.
The commercial route avoids medicine entirely. The company is finding cosmetic ingredients rather than drugs, so there is no regulatory approval to seek, only a standardised industry name and safety testing under OECD guidelines that member countries accept from one another.
That last detail is where Europe enters. The EU banned animal testing for cosmetics more than a decade ago, which made validated alternative methods a requirement rather than an ethical preference.
Brussels has since gone considerably further. The Commission adopted a roadmap on 1 June to phase out animal testing in chemical safety assessment, with more than 30 recommendations, in a market where AI biology is moving faster than the validation systems around it.
Europe wrote the demand and America is building the supply. Outer is not alone in trying, with Vivodyne raising close to $80mn for lab-grown human tissue and a field of organ-on-chip companies chasing the same preclinical market.
What Outer claims as its moat is unfashionably physical. There is no biology internet to scrape, its data exists nowhere else, and it runs its models on its own machines because it does not want that data in the cloud, which is a different bet from the one most AI companies are making.
Get the TNW newsletter
Get the most important tech news in your inbox each week.